52 completed, 13 recruiting, 13 terminated, 13 unknown. 109 Phase 2, 20 Phase 1, 4 Phase 3.
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B GST-HG141, GST-HG131, GST-HG141 Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 80 | 2026-07-10 | 2026-07-17 |
| A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B AHB-137, Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 320 | 2026-06-05 | 2026-07-29 |
| A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine - Chronic Hepatitis b | Phase 1 / Phase 2 | Not yet recruiting | Vaxine Pty Ltd | 40 | 2026-03-01 | 2025-09-22 |
| A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102, HT-101 placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 60 | 2025-11-05 | 2025-11-24 |
| A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) AHB-137, NA therapy - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 200 | 2025-09-04 | 2026-08-05 |
| A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa - Chronic Hepatitis B | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 209 | 2025-09-02 | 2026-01-15 |
| A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) AHB-137 - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 20 | 2025-07-15 | 2026-08-10 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects TQA3605 tablets Placebo, TQA3605 Tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 2 | Withdrawn | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-07-09 | 2025-08-03 | |
| A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B HTS 20mg, HTS 30mg, HTS 40mg - Chronic Hepatitis B | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 1444 | 2025-07-01 | 2025-10-02 |
| TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac), TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac) - Chronic Hepatitis B | Phase 1 / Phase 2 | Recruiting | Michael Hoelscher | 81 | 2025-06-12 | 2026-06-11 |
| A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs AHB-137, Peg-IFN, Hepatitis B Vaccine - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 200 | 2025-06-08 | 2026-07-29 |
| VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B VIR-2218 and peginterferon alfa-2a - Chronic Hepatitis B | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 12 | 2025-01-31 | 2026-10-05 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102 - Chronic Hepatitis B | Phase 1 / Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 86 | 2024-12-30 | 2025-09-19 |
| Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB) AHB-137, NAs, Placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 105 | 2024-12-13 | 2026-07-29 |
| Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) - Chronic Hepatitis B | Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 116 | 2024-12-04 | 2026-09-11 |
| Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B Imdusiran (AB-729) - Chronic Hepatitis B | Phase 2 | Recruiting | University of Maryland, Baltimore | 10 | 2024-07-25 | 2025-09-11 |
| A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B HRS-5635 Injection, HRS-5635 Injection (low dose) and Peg-IFN-α, HRS-5635 Injection (high dose) and Peg-IFN-α - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 369 | 2024-06-06 | 2025-11-17 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B TQA3810 tablets+NUC, Placebo+NUC - Chronic Hepatitis B | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 90 | 2024-03-20 | 2024-08-22 |
Showing 20 of 109. Sign in to see all of them.
Hepatitis B, Chronic (109) · Hepatitis B (21) · Hepatitis (6) · Bronchiolitis Obliterans Syndrome (2) · Liver Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Fibrosis (1) · Glomerulonephritis (1) · Heartburn (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Hepatitis D (1) · Hepatitis D, Chronic (1) · Hepatitis, Chronic (1) · Polyarteritis Nodosa (1)
Blood-Borne Infections (109) · Chronic Disease (109) · Communicable Diseases (109) · DNA Virus Infections (109) · Digestive System Diseases (109) · Disease Attributes (109) · Hepadnaviridae Infections (109) · Hepatitis, Viral, Human (109) · Infections (109) · Pathologic Processes (109) · Pathological Conditions, Signs and Symptoms (109) · Hepatitis, Chronic (108) · Virus Diseases (108) · Liver Diseases (107) · Hepatitis (103)
entecavir (23) · Tenofovir (16) · peginterferon alfa-2a (12) · tenofovir alafenamide (9) · nas (4) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (3) · Emtricitabine (3) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (3) · hepatitis B hyperimmune globulin (3) · selgantolimod (3) · ARC-520 (2) · GST-HG131 (2) · Hepatitis B Vaccines (2) · Interferon alpha-2 (2) · Lamivudine (2)
Gilead Sciences (15) · Assembly Biosciences (8) · Ausper Biopharma Co., Ltd. (6) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · Bristol-Myers Squibb (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · The Second Affiliated Hospital of Chongqing Medical University (4) · Chongqing Jiachen Biotechnology Ltd. (3) · Fujian Akeylink Biotechnology Co., Ltd. (3) · LG Life Sciences (3) · Arrowhead Pharmaceuticals (2) · Qilu Pharmaceutical Co., Ltd. (2) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · Suzhou HepaThera Biotech Co., Ltd. (2) · Third Affiliated Hospital, Sun Yat-Sen University (2)
China (52) · United States (25) · New Zealand (17) · South Korea (17) · Hong Kong (16) · Canada (13) · Australia (11) · Taiwan (11) · United Kingdom (8) · Germany (6) · Italy (6) · France (5) · Thailand (5) · Singapore (4) · Moldova (3)
Guiqiang Wang (4) · Hong Ren, MM (4) · Marc G Ghany, M.D. (3) · Jinlin Hou, PhD (2) · Junqi Niu, PhD (2) · Lai Wei, Ph.D. (2) · Yan Wang (2) · Anastacio M Hoyumpa, Prof. M.D. (1) · Charles T Leach, Prof. M.D. (1) · Ching-Lung Lai, Dr (1) · Christophe Hezode (1) · Dave Sprengers, MD, PhD (1) · Dazhi Zhang (1)
PMID 20091678, PMID 16871563, PMID 17302367, PMID 18191272, PMID 18199519, PMID 18808318, PMID 19052126, PMID 19223649, PMID 19998272, PMID 20600025, PMID 21254162, PMID 24394187, PMID 24555998, PMID 24995515, PMID 29104121, PMID 29378197, PMID 29851204, PMID 30930022, PMID 32147484, PMID 33437904, PMID 34029994, PMID 34396571, PMID 34558823, PMID 34741731, PMID 35460726, PMID 35697332, PMID 37055910, PMID 37290591, PMID 38133554, PMID 38510983, PMID 38901444, PMID 39389081, PMID 39425534, PMID 39815989, PMID 40744841, PMID 40808966, PMID 41443982, PMID 42865026
2014 (2), 2016 (2), 2009 (1), 2015 (1), 2019 (1), 2023 (1)